A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel.

George T Grossberg, Angela Sanford, C Brendan Montano, Anton P Porsteinsson, Susan Scanland, Chad Worz, Shirley McMillian, Alireza Atri
{"title":"A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel.","authors":"George T Grossberg, Angela Sanford, C Brendan Montano, Anton P Porsteinsson, Susan Scanland, Chad Worz, Shirley McMillian, Alireza Atri","doi":"10.1080/00325481.2025.2517535","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Agitation in Alzheimer's dementia has a substantial impact on patients, caregivers/family, and healthcare systems. As new evidence surrounding the treatment of agitation emerges, a roundtable of multispecialty experts convened to review published literature (from a PubMed database search on 1 October 2024) and provide evidence-based clinical practice consensus recommendations for the diagnosis and management of agitation in Alzheimer's dementia for US-based primary care providers.</p><p><strong>Aim: </strong>The main objective of this article is to summarize key recommendations from the roundtable on identification, differential diagnosis, current clinical practice, nonpharmacologic interventions, pharmacologic interventions, and treatment and communication considerations for residential care facilities/home care settings and caregivers.</p><p><strong>Results: </strong>Active communication between healthcare providers, patients, and caregivers/family is critical for early recognition, accurate diagnosis, and appropriate management and prevention of agitation. The foundation of treatment always begins with individualized psychoeducation and nonpharmacologic interventions based on the patient's personality, interests, and level of functioning. Pharmacologic interventions are strongly considered when agitated behaviors become highly intense, disturbing, and disruptive or if major safety concerns cannot be otherwise addressed, and only when the healthcare provider is confident that the agitation can be sufficiently managed or mitigated with a pharmacologic intervention possessing a favorable individual risk-benefit profile. While several pharmacologic agents have been studied in high-quality clinical trials for the treatment of agitation in Alzheimer's dementia, brexpiprazole is the only US Food and Drug Administration - approved treatment and it can be prescribed if warranted. Interventions should be continuously evaluated to optimize treatment and monitor and minimize potential side effects. A patient-centered approach that includes a strong partnership with caregivers/family as a vital part of the patient's larger care team is encouraged.</p><p><strong>Conclusion: </strong>Following these recommendations for timely detection, accurate diagnosis, and appropriate management of agitation in patients with Alzheimer's dementia is likely to improve outcomes for most patients and caregivers.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"1-17"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postgraduate medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/00325481.2025.2517535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Agitation in Alzheimer's dementia has a substantial impact on patients, caregivers/family, and healthcare systems. As new evidence surrounding the treatment of agitation emerges, a roundtable of multispecialty experts convened to review published literature (from a PubMed database search on 1 October 2024) and provide evidence-based clinical practice consensus recommendations for the diagnosis and management of agitation in Alzheimer's dementia for US-based primary care providers.

Aim: The main objective of this article is to summarize key recommendations from the roundtable on identification, differential diagnosis, current clinical practice, nonpharmacologic interventions, pharmacologic interventions, and treatment and communication considerations for residential care facilities/home care settings and caregivers.

Results: Active communication between healthcare providers, patients, and caregivers/family is critical for early recognition, accurate diagnosis, and appropriate management and prevention of agitation. The foundation of treatment always begins with individualized psychoeducation and nonpharmacologic interventions based on the patient's personality, interests, and level of functioning. Pharmacologic interventions are strongly considered when agitated behaviors become highly intense, disturbing, and disruptive or if major safety concerns cannot be otherwise addressed, and only when the healthcare provider is confident that the agitation can be sufficiently managed or mitigated with a pharmacologic intervention possessing a favorable individual risk-benefit profile. While several pharmacologic agents have been studied in high-quality clinical trials for the treatment of agitation in Alzheimer's dementia, brexpiprazole is the only US Food and Drug Administration - approved treatment and it can be prescribed if warranted. Interventions should be continuously evaluated to optimize treatment and monitor and minimize potential side effects. A patient-centered approach that includes a strong partnership with caregivers/family as a vital part of the patient's larger care team is encouraged.

Conclusion: Following these recommendations for timely detection, accurate diagnosis, and appropriate management of agitation in patients with Alzheimer's dementia is likely to improve outcomes for most patients and caregivers.

美国医生阿尔茨海默氏痴呆患者躁动的诊断、评估和循证治疗指南——专家多专业咨询小组的建议。
阿尔茨海默氏痴呆症患者的躁动对患者、护理人员/家庭和医疗保健系统产生重大影响。随着围绕躁动治疗的新证据出现,多专业专家召开了一次圆桌会议,审查已发表的文献(来自2024年10月1日的PubMed数据库搜索),并为美国初级保健提供者提供基于证据的临床实践共识建议,以诊断和管理阿尔茨海默氏痴呆症患者的躁动。本文的主要目的是总结圆桌会议关于识别、鉴别诊断、当前临床实践、非药物干预、药物干预、治疗和沟通方面的关键建议,这些建议适用于寄宿护理机构/家庭护理机构和护理人员。医疗保健提供者、患者和护理人员/家属之间的积极沟通对于早期识别、准确诊断以及适当的管理和预防躁动至关重要。治疗的基础总是从个性化的心理教育和基于患者个性、兴趣和功能水平的非药物干预开始。当激动行为变得高度强烈、令人不安和破坏性时,或者当主要的安全问题无法通过其他方式解决时,只有当医疗保健提供者确信激动可以通过具有有利个体风险-收益特征的药物干预得到充分管理或减轻时,才强烈考虑药物干预。虽然有几种药物已经在高质量的临床试验中用于治疗阿尔茨海默氏痴呆患者的躁动,但brexpiprazole是唯一获得美国食品和药物管理局批准的治疗药物,如果有必要,可以开处方。干预措施应持续评估,以优化治疗,监测和尽量减少潜在的副作用。鼓励以患者为中心的方法,包括与护理人员/家属建立牢固的伙伴关系,作为患者更大的护理团队的重要组成部分。遵循这些及时发现、准确诊断和适当管理阿尔茨海默氏痴呆症患者躁动的建议,可能会改善大多数患者和护理人员的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信